Results 11 to 20 of about 22,470,337 (287)
The impact of molecular alterations and the immune microenvironment on the natural history of Follicular Lymphoma including transformation to Diffuse Large B cell Lymphoma [PDF]
, 2009 PhDThe natural history of follicular lymphoma is heterogeneous with numerous relapses and remissions over many years. A substantial number of patients suffer an aggressive disease course with death due to disease within 5 years of diagnosis.
Lee, Abigail Mary
core +4 more sources
Heliyon, 2023 Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive B-lymphocyte-derived malignant proliferative disease that is currently one of the leading causes of death in HIV patients.
Tao Peng fei, Hui Ru Xi, Min Hai yan
doaj +1 more source
Intravascular diffuse large B-cell lymphoma with acquired ichthyosis: A case report
SAGE Open Medical Case Reports, 2023 Intravascular diffuse large B-cell lymphoma is an exceedingly rare subtype of B-cell lymphomas. This cancer is often associated with poor prognosis and can be lethal if left untreated.
Zainab Ridha +3 more
doaj +1 more source
The potential therapeutic role of selenium in diffuse large B-cell lymphoma [PDF]
, 2011 PhDThe clinical background to this work confirms the very poor outcome of patients with recurrent diffuse large B-cell lymphoma (DLBCL) and highlights the need for better therapies.
Kassam, Shireen
core +4 more sources
Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India
South Asian Journal of Cancer, 2019 Background: Gastrointestinal tract (GIT) is the most common extranodal site for non-Hodgkin's lymphoma (NHL) and constitutes about 10%-15% of all NHL. This was a prospective study to evaluate the epidemiological, clinicopathological characteristics, and ...
Babu Suresh +12 more
doaj +1 more source
Lenalidomide in Diffuse Large B-Cell Lymphomas [PDF]
Advances in Hematology, 2012 Diffuse Large B-cell Lymphomas (DLBCL) are the most frequent Non-Hodgkin Lymphomas (NHL). The addition of Rituximab to the standard chemotherapy CHOP improved the outcome in this patients, but so far 40% of patients experienced relapse or progressive disease.
Annalisa Chiappella, Umberto Vitolo
openaire +3 more sources
Haematologica, 2010 Background Multiparameter flow cytometry allows the detection of minor monoclonal B-cell populations. Using this technique combined with morphology, we were struck by the presence of minor populations of small monoclonal B cells in bone marrows of ...
Anne M. Tierens +6 more
doaj +1 more source
Journal of Medical Case Reports, 2020 Background Epstein-Barr virus is associated with many human hematopoietic neoplasms; however, Epstein-Barr virus-positive mucosa-associated lymphoid tissue lymphoma is extremely rare.
Vadim R. Gorodetskiy +6 more
doaj +1 more source
Lenalidomide in Diffuse Large B-Cell Lymphoma [PDF]
Advances in Hematology, 2012 Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma (NHL) in adults. Even if the natural history of DLBCL has been improved with the advent of immunochemotherapy, the survival results obtained with current treatment options clearly indicate that new agents or novel approaches are needed.
Catherine Thieblemont +2 more
openaire +3 more sources
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs
Haematologica, 2017 Histone methylation and demethylation regulate B-cell development, and their deregulation correlates with tumor chemoresistance in diffuse large B-cell lymphoma, limiting cure rates. Since histone methylation status correlates with disease aggressiveness
Rohit Mathur +9 more
doaj +1 more source